Skip to main content
S&P 5007,572.81+0.42%DOW51,724.05-0.50%NASDAQ25,397.74+0.93%BTC$77,611.00+0.84%ETH$2,293.36+1.84%GOLD$3,938.50-0.78%OIL$96.09-0.38%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACHV

Achieve Life Sciences, Inc.

Healthcare · Biotechnology

$6.61

Up+$0.12 (+1.81%)

Updated Nov 3, 2026, 5:32 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
242.75M
P/E ratio
-3.02
Dividend yield
0.00%
52-week range
$2.62 – $8.64
Volume
1.53M
Avg. volume
651.46K

Price performance · ACHV

ACHV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ACHV closed at $6.61 after 21 trading sessions, down 5.71% for the selected period.

Last close
$6.61
Period change
-5.71%
Period low
$6.38
Period high
$7.41
Daily close
View OHLC price history
ACHV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$6.89$6.89$6.33$6.611.53M
Oct 30, 2026$7.12$7.29$6.57$6.831.38M
Oct 29, 2026$6.90$7.23$6.90$7.191.38M
Oct 28, 2026$6.85$6.97$6.675$6.85966.18K
Oct 27, 2026$6.59$6.94$6.45$6.931.49M
Oct 26, 2026$6.53$6.65$6.46$6.54701.51K
Oct 23, 2026$6.48$6.61$6.36$6.49590.15K
Oct 22, 2026$6.39$6.64$6.33$6.50963.34K
Oct 21, 2026$6.49$6.67$6.38$6.512.47M
Oct 20, 2026$6.58$6.935$6.47$6.512.11M
Oct 19, 2026$6.54$6.735$6.455$6.605823.32K
Oct 16, 2026$6.98$7.02$6.22$6.381.99M
Oct 15, 2026$7.00$7.13$6.83$6.971.2M
Oct 14, 2026$6.98$7.11$6.83$7.001.64M
Oct 13, 2026$7.00$7.20$6.92$7.001.65M
Oct 12, 2026$7.39$7.4473$7.045$7.06948.7K
Oct 9, 2026$7.20$7.48$7.14$7.41987.3K
Oct 8, 2026$7.14$7.32$7.05$7.191.11M
Oct 7, 2026$7.02$7.3499$6.96$7.241.04M
Oct 6, 2026$7.06$7.23$6.8901$7.031.06M
Oct 5, 2026$7.24$7.3394$6.83$7.011.7M

Latest ACHV news

The latest Smart Investors Daily articles mentioning ACHV.

Stock researchCompany · Overview

ACHV research

Overview

Company profile and research snapshot.

Company profile

Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$4.75
Implied upside
—
Analysts
14
ACHV recent ratings
DateFirmRatingTarget
Sep 30, 2026StifelBuy—
Aug 13, 2026Morgan StanleyOverweight—
Jun 22, 2026HC Wainwright & Co.Buy—
Apr 21, 2026Canaccord GenuityBuy—
Apr 16, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026

Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year Among the participants new to cytisinicline (prior attempt on placebo), 39% had quit at the end of the year Participants were in their mid-fifties on average, ranging up to age 79, and many had a history of chronic conditions; the typical participant who smoked had made five quit attempts before ORCA-OL, and every p

Yahoo · Oct 15, 2026

Lisata adds biopharma finance veteran Jeffrey Farrow to board

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors. Farrow fills a newly created seat, expanding the board from seven to eight members. He will also serve on the Audit Committee. “Jeff has...

Yahoo · Oct 7, 2026

Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications

Brings 15 years of pharma launch, health system, and direct-to-patient engagement experience as Achieve prepares for potential commercialization of cytisiniclineSEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of

Yahoo · Oct 6, 2026

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By